Similar articles

• Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

  Ordóñez-Navadijo Á, Fuertes-Yebra E, Acosta-Iborra B, Balsa E, Elorza A, Aragonés J, Landazuri MO. Ordóñez-Navadijo Á, et al. Oncogene. 2016 Feb 4;35(5):587-94. doi: 10.1038/onc.2015.113. Epub 2015 Apr 27. Oncogene. 2016. PMID: 25915846
• Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.

  Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Krieg M, et al. Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938. Oncogene. 2000. PMID: 11114720
• Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.

  Damjanovic SS, Ilic BB, Beleslin Cokic BB, Antic JA, Bankovic JZ, Milicevic IT, Rodic GS, Ilic DS, Todorovic VN, Puskas N, Tulic CD. Damjanovic SS, et al. Exp Mol Pathol. 2016 Dec;101(3):323-331. doi: 10.1016/j.yexmp.2016.11.003. Epub 2016 Nov 12. Exp Mol Pathol. 2016. PMID: 27845047
• The HIF and other quandaries in VHL disease.

  Tarade D, Ohh M. Tarade D, et al. Oncogene. 2018 Jan 11;37(2):139-147. doi: 10.1038/onc.2017.338. Epub 2017 Sep 18. Oncogene. 2018. PMID: 28925400 Review.
• The VHL tumor suppressor and HIF: insights from genetic studies in mice.

  Kapitsinou PP, Haase VH. Kapitsinou PP, et al. Cell Death Differ. 2008 Apr;15(4):650-9. doi: 10.1038/sj.cdd.4402313. Epub 2008 Jan 25. Cell Death Differ. 2008. PMID: 18219317 Free PMC article. Review.